what-when-how
In Depth Tutorials and Information
O THER JOINT INVOLVEMEN T
[7] Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Abou
El-Saoud AM. Variation of matrix metalloproteinase 1 and 3
haplotypes and their serum levels in patients with rheuma-
toid arthritis and osteoarthritis. Genet Test Mol Biomarkers
2012;16(1):15-20.
[8] Chapman K, Valdes AM. Genetic factors in OA pathogenesis.
Bone 2012;51(2):258-64.
[9] Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis.
Nat Rev Rheumatol 2011;7(1):43-9.
There have been few case reports of other forms of
arthritis in patients with OI. Three patients with OI tarda
were reported to have hyperuricemia and gout. 27 There
has been one case report of a relapsing inflammatory
monoarthritis in a knee of a 47-year-old man with OI. 28
There was also a case reported of a 14-year-old girl who
developed severe osteoporosis and destructive general-
ized arthritis, initially concerning for juvenile rheuma-
toid arthritis, but later thought to be a variant of OI with
chronic arthropathy. 29 There has also been a case reported
of a 51-year-old woman with knee pain and stiffness and
hand deformities suggestive of rheumatoid arthritis but
without any hand pain or morning stiffness. 30
Beighton and colleagues reported a study of 153 sub-
jects with OI from 84 families in South Africa in order to
document the skeletal complications. 31 Seventy-nine of
153 patients had mild type I OI. They are described to
have mild orthopedic complications and relatively nor-
mal stature with fewer fractures and deformities. Twenty-
one patients with type III OI had multiple fractures, trunk
shortening and severe kyphoscoliosis. Seventeen patients
had type IV OI and were handicapped secondary to bone
fragility and long bone bowing.
One hundred women with OI with a total of 213
pregnancies between 1957 and 1998 were interviewed
by phone to assess musculoskeletal problems that they
may have encountered during the pregnancy. This
study showed that the majority of the pregnancies were
in women with type I OI and the most common symp-
tom recorded was back pain. There was no relationship
between the severity of the pain and the Sillence type
of OI. Height loss, disc prolapse and fractures were also
reported and one woman developed recurrent ankle
sprains thought to be secondary to ligamentous laxity. 32
[10]
Goldring MB, Otero M. Inlammation in osteoarthritis. Curr
Opin Rheumatol 2011;23(5):471-8.
[11]
Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP,
Fahmi H. Role of proinlammatory cytokines in the pathophysi-
ology of osteoarthritis. Nat Rev Rheumatol 2011;7(1):33-42.
[12]
Goldring SR. The role of bone in osteoarthritis pathogenesis.
Rheum Dis Clin North Am 2008;34(3):561-71.
[13]
Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat
Rev Rheumatol 2012;8:665-73.
[14]
Ashraf S, Walsh DA. Angiogenesis in osteoarthritis. Curr Opin
Rheumatol 2008;20(5):573-80.
[15]
Goldring MB. Chondrogenesis, chondrocyte differentiation, and
articular cartilage metabolism in health and osteoarthritis. Ther
Adv Musculoskelet Dis 2012;4(4):269-85.
[16]
Castaneda S, Roman-Blas JA, Largo R, Herrero-Beaumont G.
Subchondral bone as a key target for osteoarthritis treatment.
Biochem Pharmacol 2012;83(3):315-23.
[17]
Pan J, Wang B, Li W, Zhou X, Scherr T, Yang Y, et  al. Elevated
cross-talk between subchondral bone and cartilage in osteoar-
thritic joints. Bone 2012;51(2):212-7.
[18]
Bellido M, Lugo L, Roman-Blas JA, Castaneda S, Calvo E,
Largo R, et  al. Improving subchondral bone integrity reduces
progression of cartilage damage in experimental osteoarthri-
tis preceded by osteoporosis. Osteoarthritis Cartilage 2011;
19(10):1228-36.
[19]
Castaneda S, Roman-Blas JA, Largo R, Herrero-Beaumont G.
Subchondral bone as a key target for osteoarthritis treatment.
Biochem Pharmacol 2012;83(3):315-23.
[20]
Tat SK, Pelletier JP, Velasco CR, Padrines M, Martel-Pelletier J.
New perspective in osteoarthritis: the OPG and RANKL system
as a potential therapeutic target? Keio J Med 2009;58(1):29-40.
[21]
Pilichou A, Papassotiriou I, Michalakakou K, Fessatou S,
Fandridis E, Papachristou G, et al. High levels of synovial luid
osteoprotegerin (OPG) and increased serum ratio of receptor
activator of nuclear factor-kappa B ligand (RANKL) to OPG cor-
relate with disease severity in patients with primary knee osteo-
arthritis. Clin Biochem 2008;41(9):746-9.
References
[1] Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K,
et al. Development of criteria for the classiication and report-
ing of osteoarthritis. Classiication of osteoarthritis of the knee.
Diagnostic and therapeutic criteria committee of the american
rheumatism association. Arthritis Rheum 1986;29(8):1039-49.
[2] Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W,
et  al. OARSI-FDA initiative: deining the disease state of osteo-
arthritis. Osteoarthritis Cartilage 2011;19(5):478-82.
[3] Prockop DJ, Kivirikko KI. Heritable diseases of collagen. N Engl
J Med 1984;311(6):376-86.
[4] Foss MV, Byers PD. Bone density, osteoarthrosis of the hip, and
fracture of the upper end of the femur. Ann Rheum Dis 1972;
31(4):259-64.
[5] Hochberg MC, Meyer JM. Osteoarthritis. In Maricic M, Gluck
OS, eds: Bone Disease in Rheumatology. Lippincott Williams &
Wilkins, Philadelphia, PA. 2005, p. 91-6.
[6] Valdes AM, Spector TD. The contribution of genes to osteoar-
thritis. Med Clin North Am 2009;93(1):45-66. x.
[22]
Blair-Levy JM, Watts CE, Fiorentino NM, Dimitriadis EK,
Marini JC, Lipsky PE. A type I collagen defect leads to rapidly
progressive osteoarthritis in a mouse model. Arthritis Rheum
2008;58(4):1096-106.
[23]
McKiernan FE. Musculoskeletal manifestations of mild
osteogenesis imperfecta in the adult. Osteoporos Int 2005;
16(12):1698-702.
[24]
Papagelopoulos PJ, Morrey BF. Hip and knee replacement in
osteogenesis imperfecta. J Bone Joint Surg Am 1993;75(4):572-80.
[25]
Chaus GW, Heare T. End-stage posttraumatic osteoarthri-
tis treated with THA in osteogenesis imperfecta. Orthopedics
2012;35(6):e950-3.
[26]
Rousseau JC, Chevrel G, Schott AM, Garnero P. Increased carti-
lage type II collagen degradation in patients with osteogenesis
imperfecta used as a human model of bone type I collagen alter-
ations. Bone 2010;46(4):897-900.
[27]
Allen GE, Rogers FB, Lansbury J. Osteogenesis imperfecta tarda
with hyperuricemia and gout; report of three cases. Am J Med
Sci 1955;230(1):30-2.
 
Search WWH ::




Custom Search